Señales en vivo de KZA.AX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 nov 2023 @ 00:10):

Stats
Volumen de hoy	454 181
Volumen promedio	473 092
Capitalización de mercado	18.91M
EPS	$0 ( 2024-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.727
ATR14	$0.00800 (10.00%)

Volumen Correlación

Largo: -0.67 (moderate negative)

Corto: 0.15 (neutral)

Signal:(43.949) Neutral

Kazia Therapeutics Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kazia Therapeutics Ltd Correlación - Moneda/Commodity

-0.60
( weak negative )

0.20
( neutral )

0.00
( neutral )

-0.52
( weak negative )

0.63
( weak )

Kazia Therapeutics Ltd Finanzas

Annual	2022
Ingresos:	$555.00
Beneficio Bruto:	$555.00 (100.00 %)
EPS:	$-0.110

FY	2022
Ingresos:	$555.00
Beneficio Bruto:	$555.00 (100.00 %)
EPS:	$-0.110

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.190

FY	2021
Ingresos:	$15.18M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0716

Financial Reports:

No articles found.

Kazia Therapeutics Ltd

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.